Enanta Pharmaceuticals, Inc. Announces Data Presentations On Regimens Containing Protease Inhibitor ABT-450 To Be Presented At The European Association For The Study Of The Liver (EASL) Meeting

Published: Mar 24, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced eight studies have been accepted for presentation at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in London April 9-12, 2014. These presentations will report results of regimens containing ABT-450, Enanta’s lead protease inhibitor for hepatitis C virus (HCV) identified in its ongoing collaboration with AbbVie. Abstracts can now be viewed at the EASL website at www.easl.eu.

Help employers find you! Check out all the jobs and post your resume.

Back to news